Multiple Sclerosis Community
good article in NY Times today
About This Community:

Our Patient-to-Patient MS Forum is where you can communicate with other people who share your interest in Multiple Sclerosis. This forum is not monitored by medical professionals.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

good article in NY Times today

Hope for Patients With M.S.

By LAURIE TARKAN

Published: December 26, 2011

Three years ago, Kristie Salerno Kent, a singer-songwriter, was standing in a security line at the airport on her way home from a gig when her legs went numb. “From the waist down, it felt as though I was trying to walk through a bowl of oatmeal,” said the 38-year-old musician, who has multiple sclerosis.


She inched her way to a security officer, who called for a wheelchair and helped remove her shoes and belt to get her through security. Frightened and embarrassed, she was taken to her gate in a wheelchair.

Three months later, she experienced another flare-up. While giving a live television interview about a short film she had made on living with M.S., she suddenly lost her ability to speak. “It was as if my mouth was packed with marbles,” she said. “I kept trying to say, ‘I’m sorry,’ to the reporter, but nothing came out that made sense.”

The medication she was taking to prevent these attacks was losing its effect, so her doctor suggested she switch to Tysabri, one of the newer, more potent “disease-modifying drugs,” which reduce the severity and frequency of relapses. She also began taking Ampyra, which early last year became the first drug approved to treat any M.S. symptom. She hasn’t had a flare-up since.

After decades of basic research on M.S., the last five years have brought a rapid rollout of new and sophisticated drugs that are changing how this disease is managed and offering patients new hope.

“We have a disease that’s gone from having no treatments 20 years ago to having multiple treatment options,” said Dr. Timothy Coetzee, the chief research officer at the National Multiple Sclerosis Society. “There is a growing recognition that M.S. is becoming a manageable disease.”

In M.S., the body’s immune system damages neurons in the brain and spinal cord, attacking the myelin sheath that insulates these nerves. About 85 percent of patients start out with what is called relapsing-remitting M.S., characterized by flare-ups or attacks that cause lesions to form on the brain and that affect the ability to walk, to see and to control the bladder, among other neurological impairments.

These attacks are short-lived, and patients typically recover from them. But more than half of patients eventually develop a progressive form of M.S., causing the permanent loss of these functions.

Once that happens, many of the treatments are ineffective. But the new drugs may slow, perhaps even prevent, the progression that was once considered inevitable for many patients.

“The drugs we now have are shifting what the natural history of the disease looks like,” said Dr. Coetzee.

Doctors can now choose from eight disease-modifying drugs, which reduce relapses and thereby slow the progression of the disease. Some of the drugs also prevent brain neurons from dying off, now thought to be a major cause of permanent disability.

There have also been advances in treating specific symptoms of M.S. Within the past two years, three medications have been approved specifically for M.S. symptoms: Ampyra to improve walking, Nuedexta for uncontrollable laughing or crying, and Botox for urinary incontinence and spasticity in upper limbs.

“We’re shooting for disease-free status, where someone with M.S. is on a medicine and has no sign of M.S.,” said Dr. Richard Rudick, director of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic.

The first generation of M.S. drugs included mostly immune-suppressing interferons delivered via injection or infusion. These are still the most widely used, reducing relapses by about one-third. The new drugs are more sophisticated, targeting specific molecules involved in the disease, rather than simply tamping down the immune system to reduce inflammation in the brain.

Just last year, the first oral drug for M.S., Gilenya, gained approval with data showing it cut the relapse rate by 55 percent. Gilenya causes inflammatory cells called lymphocytes to get trapped in lymph nodes so they don’t travel to the brain, where they would damage neurons.

Patients need to be monitored for several potentially serious side effects, including a slowed heart rate and liver and vision problems. One patient recently died 24 hours after starting on Gilenya; the Food and Drug Administration is investigating the cause of the death.

The most potent drug, Tysabri, reduces the relapse rate by about 70 percent, but it comes with a small risk of a fatal brain infection caused by a common virus. Patients may be screened for antibodies to the virus; the risk of infection is considered quite low in those with no sign of the antibodies, and they are given the drug.

At least four other drugs with different mechanisms are in Phase 3 clinical trials and could win approval within the next year, experts say. Some work by protecting nerves from damage.

“There’s a lot of focus on developing drugs that inhibit or stop this neurodegeneration, which we believe is the underlying cause for difficulty walking, leading people to require a wheelchair,” said Dr. Rudick.

One of the new neuroprotective drugs, called BG-12, captured wide attention at an annual international conference on M.S. in Amsterdam in October. Researchers reported a 53 percent reduction in relapses in patients taking it and a greater than 30 percent reduction of permanent disability progression over a two-year period. It also appears to have fewer risks than equally potent drugs like Gilenya.

“This might be the drug that would completely displace the interferons,” said Dr. Timothy L. Vollmer, director of neurology clinical research at the University of Colorado.

Although many doctors start patients on interferons first because of lower risks, there is a growing recognition that treating patients aggressively and early with the newer medications can preserve brain neurons and possibly prevent the progression of the disease.

But treating M.S. is still difficult. Many treatments come with serious side effects and other risks, and some people simply don’t respond to them. Patients progress at different rates, and the symptoms vary from one patient to another. Some people cannot tolerate certain medications.

“The biggest frustration is the huge uncertainty,” said Dr. Jerome J. Graber, an assistant professor of neurology at Montefiore Medical Center in the Bronx. “I still can’t predict who will progress and what’s the best way to treat someone.”

Still, some patients are beginning to see a more hopeful prognosis. After Ms. Salerno Kent started taking Tysabri and Ampyra, her walking improved enough for her to go hiking with husband and son, her speech issues resolved, and she felt much more confident when singing on stage.

“We have so many more options now, and I realize that we no longer have to give up the quality of life because we have M.S.,” she said. “We’ve always expected to deteriorate with time, but I realize that this is not acceptable anymore.”


http://www.nytimes.com/2011/12/27/health/new-drugs-raise-hope-for-patients-with-ms.html?_r=1

Related Discussions
5 Comments Post a Comment
Blank
382218_tn?1341185087
Interesting there's no mention of CCSVI, venoplasty, Dr. Zamboni.  We're bombarded with it in the Canadian media.
Blank
572651_tn?1333939396
What a great article, DV.  I really appreciate your diligence inkeeping us up to date with these bits of information.
Blank
572651_tn?1333939396
As for CCSVI, what is there to say?  The verdict is so far out on whether this is a connection to MS or not.  
Blank
382218_tn?1341185087
I agree Lulu, that's why I wonder why in Canada it so dominates media coverage on MS....I guess because it is so controversial, and a few reporters have jumped on it and made it a pet cause.  Yet in comparison, little mention of it in U.S. media coverage, which I don't think is a bad thing.  I think the angle of many Cdn pieces is misleading, overstating the benefits or at least understating the risks of the procedure; minimizing the need for actual science to prove the theory and heavily relying on anecdotal cases to  push our provincial governments to fund the procedure.   So I'm surprised with all the noise up here that there's not much noise at all in the U.S. media, and am especially surprised as many Canadians are paying out of pocket to go to private U.S. clinics to have it done.  I will not be one of them, just in case you were wondering.  :)
3/3 cases I personally know of turned out badly, anecdotal yes, but I'm waiting for solid science to prove or disprove the value of this procedure.
Blank
1225331_tn?1333369369
I think this was a really good article - I'm glad that it listed the pros and the cons of the different meds.  Thanks for posting this.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Multiple Sclerosis Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Neurology Answerers
Avatar_f_tn
Blank
SarahL2491
Alagash, ME
Avatar_f_tn
Blank
essdipity
1831849_tn?1383231992
Blank
kwarendorf
Great Neck, NY
667078_tn?1316004535
Blank
HVAC
Durham, NC
572651_tn?1333939396
Blank
Lulu54
Dayton, OH
987762_tn?1331031553
Blank
supermum_ms
Australia